吉非替尼联合放化疗与单纯放化疗治疗非小细胞肺癌脑转移的效果  

Comparison efficacy of between gefitinib combined with chemoradiotherapy and chemoradiotherapy alone in the treatment of brain metastases from non-small cell lung cancer

作　　者：卢晓艳[1] 肖庆成[1] LU Xiaoyan;XIAO Qingcheng(The SecondWard of Cancer,Siyang County People's Hospital,Suqian,223700,Jiangsu,China)

机构地区：[1]泗阳县人民医院肿瘤二病区,江苏宿迁223700

出　　处：《当代医学》2023年第18期157-159,共3页Contemporary Medicine

摘　　要：目的比较吉非替尼联合放化疗与单纯放化疗治疗非小细胞肺癌(NSCLC)脑转移的临床疗效。方法选取2017年12月至2020年12月于本院住院治疗的102例NSCLC脑转移患者作为研究对象,根据随机数字表法分为两组,每组51例。参照组给予单纯放化疗治疗,观察组给予吉非替尼联合放化疗治疗,比较两组临床疗效、血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、细胞角蛋白19片段(CYFRA-21)水平及不良反应发生率。结果观察组治疗总有效率(90.20%)高于参照组(62.75%),差异有统计学意义(P<0.05)。治疗后,两组血清CEA、CA19-9、CYFRA-21水平均低于治疗前,且观察组低于参照组,差异有统计学意义(P<0.05)。观察组不良反应发生率(11.76%)与参照组(9.80%)比较差异无统计学意义。结论吉非替尼联合放化疗可有效控制NSCLC脑转移患者病情,降低血清肿瘤标志物水平,且不良反应较少。Objective To compare the clinical efficacy of gefitinib combined with chemoradiotherapy and chemoradiotherapy alone in the treatment of brain metastases in non-small cell lung cancer(NSCLC).Methods A total of 102 patients with brain metastases NSCLC from hospitalized in our hospital from December 2017 to December 2020 were selected as the research subjects,and they were divided into two groups according to random number table method,with 51 cases in each group.The reference group was given chemoradiotherapy alone,and the observation group was given gefitinib combined chemoradiotherapy,the clinical efficacy,serum levels of carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),cytokeratin 19 fragment(CYFRA-21)and the incidence of adverse reactions were compared between the two groups.Results The total effective rate in the observation group(90.20%)was higher than that in the reference group(62.75%),and the difference was statistically significant(P<0.05).After treatment,the serum CEA,CA19-9 and CYFRA-21 levels of the two groups were lower than before treatment,and the observation group was lower than the reference group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group(11.76%)and the reference group(9.80%).Conclusion Gefitinib combined with chemoradiotherapy can effectively control the disease of patients with brain metastases in NSCLC,reduce the level of serum tumor markers,and have fewer adverse reactions.

关 键 词：吉非替尼 放化疗 非小细胞肺癌 脑转移 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]